Your browser is no longer supported. Please, upgrade your browser.
Settings
FWBI [NASD]
First Wave BioPharma, Inc.
Index- P/E- EPS (ttm)-16.36 Insider Own0.77% Shs Outstand9.34M Perf Week-23.90%
Market Cap21.50M Forward P/E- EPS next Y-2.70 Insider Trans0.00% Shs Float9.18M Perf Month-40.00%
Income-91.50M PEG- EPS next Q-0.49 Inst Own4.60% Short Float6.34% Perf Quarter-75.11%
Sales- P/S- EPS this Y-116.80% Inst Trans-1.40% Short Ratio0.32 Perf Half Y-82.66%
Book/sh-0.75 P/B- EPS next Y- ROA-641.10% Target Price16.00 Perf Year-79.77%
Cash/sh0.52 P/C2.99 EPS next 5Y- ROE- 52W Range1.27 - 26.30 Perf YTD-83.92%
Dividend- P/FCF- EPS past 5Y-19.00% ROI- 52W High-94.07% Beta1.74
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low22.83% ATR0.23
Employees12 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)30.84 Volatility13.95% 11.66%
OptionableNo Debt/Eq- EPS Q/Q30.80% Profit Margin- Rel Volume0.35 Prev Close1.40
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.84M Price1.56
Recom- SMA20-23.77% SMA50-37.27% SMA200-77.58% Volume644,208 Change11.43%
Dec-06-21 07:00AM  
Nov-30-21 07:00AM  
Nov-16-21 07:00AM  
Oct-21-21 07:30AM  
Oct-19-21 09:24AM  
Oct-14-21 09:00AM  
Oct-12-21 08:30AM  
Oct-04-21 11:45AM  
Oct-01-21 12:30PM  
Sep-28-21 08:00AM  
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases. The company is advancing a therapeutic development pipeline populated with various clinical stage programs built around its two proprietary technologies, known as niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its niclosamide portfolio is led by three clinical programs: FW-COV for COVID-19 gastrointestinal infections; FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis; and FW-ICI-AC for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn's disease) are focused to enter into pipeline development. The company is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.